CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	bosutinib + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria bosutinib + inotuzumab ozogamicin Sensitive : C2	bosutinib + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria bosutinib + inotuzumab ozogamicin Sensitive : C2
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria inotuzumab ozogamicin Sensitive : C2	inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria inotuzumab ozogamicin Sensitive : C2
MLL rearrangement	Acute Lymphocytic Leukemia	MLL rearrangement	Acute Lymphocytic Leukemia	blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Resistant : C3	blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Resistant : C3
MLL rearrangement	Acute Lymphocytic Leukemia	MLL rearrangement	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Resistant: C3 – Early Trials inotuzumab ozogamicin Resistant : C3	inotuzumab ozogamicin Resistant: C3 – Early Trials inotuzumab ozogamicin Resistant : C3

CD22-targeted antibody-drug conjugate

CD22-targeted antibody-drug conjugate

Associations(30)

Associations
(30)